Drugs / 89Zr-Pembrolizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03065764 | Jan 2017 → Dec 2019 | non-small cell lung carcinoma | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-Pembrolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03065764 ↗ |
| Modality | Diagnostic / imaging agent | “immuno-PET scans with a non-therapeutic tracer dose” NCT03065764 ↗ |